Effect of Covid-19 vaccine on some immunological salivary biomarkers (sIgA and Interleukine-17)

Dhuha Ali, Ghada Taha
{"title":"Effect of Covid-19 vaccine on some immunological salivary biomarkers (sIgA and Interleukine-17)","authors":"Dhuha Ali, Ghada Taha","doi":"10.32007/jfacmedbagdad.2039","DOIUrl":null,"url":null,"abstract":"Background: The most widely used vaccination against SARS-associated coronavirus (SARS-CoV-2) is the Pfizer vaccine, which provides protection against this virus. However, its ability to safeguard the oral cavity is unclear, and neither are the exact immunological biomarker levels it activates.\nAim of the study: To investigate the possibility that Pfizer vaccination protects the oral cavity against Covid-19.\nPatients and Methods: The study group consisted of a total of 70 subjects (30 as the control group They were followed up before being vaccinated as non-vaccinated (maybe previously infected or non-infected or recovered) and 40 participants followed up three weeks after the first dose and one week after the second vaccination. All saliva samples were collected from the individuals in the current study at the medical city hospital in Baghdad from September 2021 to July 2022. The salivary biomarkers sIgA and IL-17 were detected by enzyme-linked immunosorbent assay (ELISA) kits.\nResult: Secretory IgA levels showed a highly significant difference (p0.05) in the followed-up group after the first vaccination compared to the non-vaccinated group (controls), however, a non-significant difference in its level was found in the followed-up group after the first vaccination compared to after the second vaccination. In contrast to healthy controls, non-vaccinated participants had greater salivary IL-17 levels. Followed-up participants’ IL-17 levels did not change significantly after the first and second vaccines (P>0.05).\nConclusion: The Pfizer vaccine had a minor impact on sIgA because mRNA vaccines protect systemically more than salivary. Nevertheless, the Pfizer vaccine raises IL-17 levels after the first and second doses without triggering cytokine syndrome.","PeriodicalId":33125,"journal":{"name":"mjl@ kly@ lTb","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"mjl@ kly@ lTb","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.32007/jfacmedbagdad.2039","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

Abstract

Background: The most widely used vaccination against SARS-associated coronavirus (SARS-CoV-2) is the Pfizer vaccine, which provides protection against this virus. However, its ability to safeguard the oral cavity is unclear, and neither are the exact immunological biomarker levels it activates. Aim of the study: To investigate the possibility that Pfizer vaccination protects the oral cavity against Covid-19. Patients and Methods: The study group consisted of a total of 70 subjects (30 as the control group They were followed up before being vaccinated as non-vaccinated (maybe previously infected or non-infected or recovered) and 40 participants followed up three weeks after the first dose and one week after the second vaccination. All saliva samples were collected from the individuals in the current study at the medical city hospital in Baghdad from September 2021 to July 2022. The salivary biomarkers sIgA and IL-17 were detected by enzyme-linked immunosorbent assay (ELISA) kits. Result: Secretory IgA levels showed a highly significant difference (p0.05) in the followed-up group after the first vaccination compared to the non-vaccinated group (controls), however, a non-significant difference in its level was found in the followed-up group after the first vaccination compared to after the second vaccination. In contrast to healthy controls, non-vaccinated participants had greater salivary IL-17 levels. Followed-up participants’ IL-17 levels did not change significantly after the first and second vaccines (P>0.05). Conclusion: The Pfizer vaccine had a minor impact on sIgA because mRNA vaccines protect systemically more than salivary. Nevertheless, the Pfizer vaccine raises IL-17 levels after the first and second doses without triggering cytokine syndrome.
新冠肺炎疫苗对某些唾液免疫生物标志物(sIgA和白细胞介素-17)的影响
背景:最广泛使用的针对sars相关冠状病毒(SARS-CoV-2)的疫苗是辉瑞公司的疫苗,它提供了对该病毒的保护。然而,它保护口腔的能力尚不清楚,它激活的确切免疫生物标志物水平也不清楚。本研究的目的:探讨辉瑞疫苗接种保护口腔免受Covid-19感染的可能性。患者和方法:研究组共包括70名受试者(30名为对照组),在未接种疫苗(可能先前感染或未感染或康复)接种疫苗前进行随访,40名参与者在第一次接种后3周和第二次接种后1周进行随访。所有唾液样本都是在2021年9月至2022年7月期间在巴格达医疗城市医院收集的。采用酶联免疫吸附试验(ELISA)试剂盒检测唾液生物标志物sIgA和IL-17。结果:第一次接种后随访组与未接种组(对照组)血清IgA水平差异极显著(p0.05),第一次接种后随访组与第二次接种后血清IgA水平差异不显著。与健康对照组相比,未接种疫苗的参与者唾液IL-17水平更高。第一次和第二次疫苗接种后,随访参与者IL-17水平无显著变化(P < 0.05)。结论:辉瑞疫苗对sIgA的影响较小,因为mRNA疫苗对全身的保护作用大于对唾液的保护作用。然而,辉瑞公司的疫苗在第一次和第二次注射后会提高IL-17水平,而不会引发细胞因子综合征。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
35
审稿时长
24 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信